Lercanidipina Zentiva

Lercanidipine hydrochloride, the active ingredient in Lercanidipina Zentiva, is a calcium channel blocker presented as an oral tablet for oral use. It is used to lower elevated blood pressure in adults diagnosed with hypertension. GNH USA supplies Lercanidipina Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium‑channel blocker indicated for the management of high‑blood‑pressure disorders. - Essential hypertension: reduces systolic and diastolic pressure in patients with primary hypertension. - Isolated systolic hypertension: helps control elevated systolic readings, especially in older adults. - Secondary hypertension (adjunct therapy): may be added to other antihypertensives when blood pressure remains uncontrolled.

Lercanidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of ankles or lower legs. - Dizziness or light‑headedness, especially when standing. - Tachycardia: increased heart rate. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Myocardial infarction: rare occurrence of heart attack. - Allergic reactions: rash, pruritus, or anaphylaxis. - Liver enzyme elevation: abnormal hepatic function tests. - Angioedema: swelling of face, lips, or tongue. - Cardiac conduction disturbances: heart block or arrhythmia.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Hepatic impairment: use with caution in patients with liver disease. - Concomitant antihypertensives: adjust doses to prevent additive effects. - Heart failure: assess cardiac status before use. - Pregnancy and lactation: evaluate risk‑benefit ratio; limited data available. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Other calcium‑channel blockers (e.g., amlodipine): risk of additive hypotension. - Grapefruit juice: enhances systemic exposure.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Beta‑blockers or ACE inhibitors: monitor for excessive blood‑pressure lowering.